- Home
- GOAI vs SPRO Comparison
GOAI vs SPRO Comparison
Compare GOAI & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOAI | SPRO |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.9M | 135.8M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | GOAI | SPRO |
|---|---|---|
| Price | $3.27 | $2.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 311.2K | 238.0K |
| Earning Date | 04-10-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | $15,656,703.00 | ★ $40,549,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.37 | ★ N/A |
| Revenue Growth | ★ 86.84 | N/A |
| 52 Week Low | $1.32 | $0.51 |
| 52 Week High | $18.00 | $3.22 |
Technical Indicators
Market Signals| Indicator | GOAI | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 34.27 |
| Support Level | N/A | $2.22 |
| Resistance Level | N/A | $2.47 |
| Average True Range (ATR) | 0.00 | 0.11 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 0.00 | 7.14 |
Price Performance
Historical ComparisonAbout SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.